|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SUPT16H |
Gene summary for SUPT16H |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SUPT16H | Gene ID | 11198 |
| Gene name | SPT16 homolog, facilitates chromatin remodeling subunit | |
| Gene Alias | CDC68 | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9Y5B9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11198 | SUPT16H | HTA11_347_2000001011 | Human | Colorectum | AD | 9.98e-11 | 4.49e-01 | -0.1954 |
| 11198 | SUPT16H | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.85e-09 | 6.42e-01 | -0.059 |
| 11198 | SUPT16H | HTA11_866_3004761011 | Human | Colorectum | AD | 3.68e-03 | 3.29e-01 | 0.096 |
| 11198 | SUPT16H | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.20e-05 | 4.25e-01 | 0.294 |
| 11198 | SUPT16H | HTA11_99999965104_69814 | Human | Colorectum | MSS | 5.50e-10 | 6.49e-01 | 0.281 |
| 11198 | SUPT16H | A015-C-203 | Human | Colorectum | FAP | 2.46e-06 | 5.18e-02 | -0.1294 |
| 11198 | SUPT16H | A015-C-104 | Human | Colorectum | FAP | 2.36e-08 | 1.99e-02 | -0.1899 |
| 11198 | SUPT16H | A001-C-014 | Human | Colorectum | FAP | 1.49e-02 | -3.51e-02 | 0.0135 |
| 11198 | SUPT16H | A002-C-016 | Human | Colorectum | FAP | 4.71e-03 | -1.76e-02 | 0.0521 |
| 11198 | SUPT16H | A002-C-116 | Human | Colorectum | FAP | 4.76e-06 | -7.64e-03 | -0.0452 |
| 11198 | SUPT16H | LZE2D | Human | Esophagus | HGIN | 2.31e-03 | 3.57e-01 | 0.0642 |
| 11198 | SUPT16H | LZE2T | Human | Esophagus | ESCC | 1.30e-07 | 1.12e+00 | 0.082 |
| 11198 | SUPT16H | LZE4T | Human | Esophagus | ESCC | 8.41e-22 | 7.83e-01 | 0.0811 |
| 11198 | SUPT16H | LZE5T | Human | Esophagus | ESCC | 2.20e-08 | 1.05e+00 | 0.0514 |
| 11198 | SUPT16H | LZE7T | Human | Esophagus | ESCC | 3.11e-05 | 3.92e-01 | 0.0667 |
| 11198 | SUPT16H | LZE8T | Human | Esophagus | ESCC | 7.60e-07 | 2.28e-01 | 0.067 |
| 11198 | SUPT16H | LZE20T | Human | Esophagus | ESCC | 8.75e-12 | 2.80e-01 | 0.0662 |
| 11198 | SUPT16H | LZE21D1 | Human | Esophagus | HGIN | 4.62e-05 | 2.02e-01 | 0.0632 |
| 11198 | SUPT16H | LZE22D1 | Human | Esophagus | HGIN | 1.61e-02 | 9.07e-02 | 0.0595 |
| 11198 | SUPT16H | LZE24T | Human | Esophagus | ESCC | 1.05e-18 | 3.72e-01 | 0.0596 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022411 | Colorectum | AD | cellular component disassembly | 147/3918 | 443/18723 | 8.53e-10 | 6.76e-08 | 147 |
| GO:0032984 | Colorectum | AD | protein-containing complex disassembly | 81/3918 | 224/18723 | 9.41e-08 | 4.65e-06 | 81 |
| GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
| GO:0032986 | Colorectum | AD | protein-DNA complex disassembly | 12/3918 | 20/18723 | 1.60e-04 | 2.21e-03 | 12 |
| GO:0031498 | Colorectum | AD | chromatin disassembly | 11/3918 | 20/18723 | 8.39e-04 | 8.21e-03 | 11 |
| GO:0006337 | Colorectum | AD | nucleosome disassembly | 10/3918 | 18/18723 | 1.31e-03 | 1.15e-02 | 10 |
| GO:0032786 | Colorectum | AD | positive regulation of DNA-templated transcription, elongation | 13/3918 | 27/18723 | 1.47e-03 | 1.25e-02 | 13 |
| GO:0006354 | Colorectum | AD | DNA-templated transcription, elongation | 31/3918 | 91/18723 | 2.46e-03 | 1.90e-02 | 31 |
| GO:0006368 | Colorectum | AD | transcription elongation from RNA polymerase II promoter | 24/3918 | 69/18723 | 5.35e-03 | 3.52e-02 | 24 |
| GO:0006338 | Colorectum | AD | chromatin remodeling | 70/3918 | 255/18723 | 7.44e-03 | 4.53e-02 | 70 |
| GO:00224112 | Colorectum | MSS | cellular component disassembly | 130/3467 | 443/18723 | 1.44e-08 | 8.46e-07 | 130 |
| GO:00329842 | Colorectum | MSS | protein-containing complex disassembly | 69/3467 | 224/18723 | 5.61e-06 | 1.50e-04 | 69 |
| GO:00329862 | Colorectum | MSS | protein-DNA complex disassembly | 12/3467 | 20/18723 | 4.55e-05 | 8.35e-04 | 12 |
| GO:00063252 | Colorectum | MSS | chromatin organization | 107/3467 | 409/18723 | 7.22e-05 | 1.21e-03 | 107 |
| GO:00314982 | Colorectum | MSS | chromatin disassembly | 11/3467 | 20/18723 | 2.77e-04 | 3.67e-03 | 11 |
| GO:00063371 | Colorectum | MSS | nucleosome disassembly | 10/3467 | 18/18723 | 4.76e-04 | 5.58e-03 | 10 |
| GO:00063541 | Colorectum | MSS | DNA-templated transcription, elongation | 29/3467 | 91/18723 | 1.52e-03 | 1.39e-02 | 29 |
| GO:00327861 | Colorectum | MSS | positive regulation of DNA-templated transcription, elongation | 12/3467 | 27/18723 | 1.74e-03 | 1.55e-02 | 12 |
| GO:00063681 | Colorectum | MSS | transcription elongation from RNA polymerase II promoter | 22/3467 | 69/18723 | 5.31e-03 | 3.62e-02 | 22 |
| GO:00224114 | Colorectum | FAP | cellular component disassembly | 97/2622 | 443/18723 | 3.44e-06 | 1.23e-04 | 97 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SUPT16H | SNV | Missense_Mutation | novel | c.121N>C | p.Asp41His | p.D41H | Q9Y5B9 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| SUPT16H | SNV | Missense_Mutation | novel | c.1921G>A | p.Glu641Lys | p.E641K | Q9Y5B9 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| SUPT16H | SNV | Missense_Mutation | c.1444G>C | p.Ala482Pro | p.A482P | Q9Y5B9 | protein_coding | tolerated(0.14) | possibly_damaging(0.759) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| SUPT16H | SNV | Missense_Mutation | c.594N>A | p.Phe198Leu | p.F198L | Q9Y5B9 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SUPT16H | SNV | Missense_Mutation | novel | c.535N>A | p.Glu179Lys | p.E179K | Q9Y5B9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SUPT16H | SNV | Missense_Mutation | novel | c.296G>C | p.Gly99Ala | p.G99A | Q9Y5B9 | protein_coding | tolerated(0.09) | benign(0.147) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SUPT16H | SNV | Missense_Mutation | novel | c.2806N>A | p.Glu936Lys | p.E936K | Q9Y5B9 | protein_coding | tolerated(0.2) | benign(0.011) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SUPT16H | SNV | Missense_Mutation | c.905N>G | p.Tyr302Cys | p.Y302C | Q9Y5B9 | protein_coding | deleterious(0) | possibly_damaging(0.877) | TCGA-D8-A1JH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | nolvadex | SD | |
| SUPT16H | SNV | Missense_Mutation | c.991N>T | p.Asp331Tyr | p.D331Y | Q9Y5B9 | protein_coding | deleterious(0.01) | possibly_damaging(0.827) | TCGA-E9-A1RG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| SUPT16H | SNV | Missense_Mutation | c.441G>A | p.Met147Ile | p.M147I | Q9Y5B9 | protein_coding | tolerated(0.81) | benign(0.011) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |